May 5th 2025
To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Watch
The Value of Virtual Physical Therapy for Musculoskeletal Care
This counterfactual simulation study on a nationally representative sample of the working population with musculoskeletal conditions estimated the value of patient-initiated virtual physical therapy.
Read More
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 8th 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Read More
What We’re Reading: Merck Sues US Government; Cancer Drug Shortages; ACA Appeals Court Hearing
June 6th 2023Merck sues to stop Medicare drug price negotiations; doctors delay lifesaving therapies due to cancer drug shortages; a federal appeals court will hear Affordable Care Act coverage prevention case.
Read More
Cost of RSV Hospitalization Could Decrease if Treatment Targets Children Younger Than 3 Months
June 5th 2023The sharp reduction in costs for hospitalization from respiratory syncytial virus (RSV) in infants 3 months and younger after the COVID-19 pandemic outweighed the cost increase for children aged 3 to 24 months.
Read More
Group Highlights Discrepancies Between Claims, Survey Cost Data Among Medicare Patients
June 4th 2023With Medicare-aged Americans accounting for over 15% of the population and significant health care costs, stakeholders have leveraged various approaches, including the Medicare Current Beneficiary Survey, for estimating costs.
Read More
Medicare Patients With HSNCC Fare Better Than Younger Counterparts
June 2nd 2023Deemed the “Medicare” effect, patients aged 65 years who have Medicare coverage had an increased incidence of head and neck squamous cell carcinoma (HNSCC) but were less likely to receive a late-stage diagnosis and had lower mortality rates.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
What We’re Reading: MA BCBS Partners With Tufts; Medicaid Drug Price Audit; SC Passes Abortion Ban
May 24th 2023Blue Cross Blue Shield in Massachusetts sets agreement with Tufts Medicine using equity benchmarks; drug prices covered by Medicaid to undergo yearly audit; South Carolina abortion ban headed to governor as Planned Parenthood announces national staff cutbacks to shift resources to the states.
Read More
Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Read More
Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.
Read More
Financial Toxicity Seen in 3 of 4 HSCT-Eligible Patients With Leukemia
May 15th 2023The researchers of a new study highlighted the unique financial burden facing these patients, eligible for hematopoietic stem cell transplantation (HSCT), who often require lengthy hospitalizations and have associated risks of acute and chronic morbidity.
Read More
Tacking Upwind: Reducing Spending Among High-risk Commercially Insured Patients
Although commercial accountable care organization populations are healthy on average, some individuals might benefit from programs for high-risk patients to mitigate high levels of health care utilization.
Read More